Quick search in Citations
This JournalAnywhereCitation
Advanced Search
Research Article
Originally Published 9 September 2022
Free Access

Outcomes of Cerebral Venous Thrombosis due to Vaccine-Induced Immune Thrombotic Thrombocytopenia After the Acute Phase

Anita van de Munckhof, MD https://orcid.org/0000-0001-6028-3426, Erik Lindgren, MD https://orcid.org/0000-0002-7628-5044, Timothy J. Kleinig, MBBS (Hons), PhD https://orcid.org/0000-0003-4430-3276, Thalia S. Field, MD, MHSc, Charlotte Cordonnier, MD, PhD https://orcid.org/0000-0002-5697-6892, Katarzyna Krzywicka, MD, MPhil https://orcid.org/0000-0002-9478-0401, Sven Poli, MD, MSc https://orcid.org/0000-0002-0286-8781, … Show All … , Mayte Sánchez van Kammen, MD, MSc https://orcid.org/0000-0001-5614-9689, Afshin Borhani-Haghighi, MD, Robin Lemmens, MD, PhD https://orcid.org/0000-0002-4948-5956, Adrian Scutelnic, MD https://orcid.org/0000-0001-9053-584X, Alfonso Ciccone, MD https://orcid.org/0000-0002-4590-3575, Thomas Gattringer, MD, PhD https://orcid.org/0000-0002-6065-6576, Matthias Wittstock, MD, PhD, Vanessa Dizonno, MSc, Annemie Devroye, Ahmed Elkady, MD, MSc, Albrecht Günther, MD https://orcid.org/0000-0002-2394-3947, Alvaro Cervera, MD, PhD https://orcid.org/0000-0002-6644-0020, Annerose Mengel, MD https://orcid.org/0000-0002-2399-3020, Beng Lim Alvin Chew, MD, Brian Buck, MD https://orcid.org/0000-0002-7984-6062, Carla Zanferrari, MD, Carlos Garcia-Esperon, MD, PhD, Christian Jacobi, MD https://orcid.org/0000-0002-9611-3805, Cristina Soriano, MD, Dominik Michalski, MD https://orcid.org/0000-0002-0206-5380, Zohreh Zamani, MD, Dylan Blacquiere, MD, Elias Johansson, MD, PhD https://orcid.org/0000-0001-5317-4563, Elisa Cuadrado-Godia, MD, PhD https://orcid.org/0000-0002-9147-875X, Fabrice Vuillier, MD, PhD, Felix J. Bode, MD https://orcid.org/0000-0003-4498-186X, François Caparros, MD https://orcid.org/0000-0002-6627-0893, Frank Maier, MD, Georgios Tsivgoulis, MD, PhD https://orcid.org/0000-0002-0640-3797, Hans D. Katzberg, MD, Jiangang Duan, MD, PhD https://orcid.org/0000-0002-8849-2120, Jim Burrow, MD, Johann Pelz, MD, Joshua Mbroh, MD, MSc https://orcid.org/0000-0002-0108-9161, Joyce Oen, MD, Judith Schouten, MD, PhD, Julian Zimmermann, MD https://orcid.org/0000-0003-1964-0078, Karl Ng, MBBS (Hons 1), PhD https://orcid.org/0000-0001-7973-3773, Katia Garambois, MD, PhD, Marco Petruzzellis, MD https://orcid.org/0000-0001-7413-6355, Mariana Carvalho Dias, MD https://orcid.org/0000-0002-6603-1796, Masoud Ghiasian, MD, Michele Romoli, MD https://orcid.org/0000-0001-8009-8543, Miguel Miranda, MD, MSc https://orcid.org/0000-0001-5285-1665, Miriam Wronski, MD https://orcid.org/0000-0003-4888-7707, Mona Skjelland, MD, PhD, Mostafa Almasi-Dooghaee, MD https://orcid.org/0000-0002-3244-1615, Pauline Cuisenier, MD, Seán Murphy, MD, Serge Timsit, MD, PhD https://orcid.org/0000-0003-0346-8576, Shelagh B. Coutts, MD, MSc https://orcid.org/0000-0001-5090-5105, Silvia Schönenberger, MD, Simon Nagel, MD https://orcid.org/0000-0003-2471-6647, Sini Hiltunen, MD, PhD, Sophie Chatterton, MD https://orcid.org/0000-0003-4296-9285, Thomas Cox, MD, Thorsten Bartsch, MD, PhD https://orcid.org/0000-0001-8387-5731, Vahid Shaygannejad, MD, Zahra Mirzaasgari, MD, Saskia Middeldorp, MD, PhD https://orcid.org/0000-0002-1006-6420, Marcel M. Levi, MD, PhD, Johanna A. Kremer Hovinga, MD https://orcid.org/0000-0002-1300-7135, Katarina Jood, MD, PhD, Turgut Tatlisumak, MD, PhD https://orcid.org/0000-0002-2430-8988, Jukka Putaala, MD, PhD https://orcid.org/0000-0002-6630-6104, Mirjam R. Heldner, MD, MSc https://orcid.org/0000-0002-3594-2159, Marcel Arnold, MD, Diana Aguiar de Sousa, MD, PhD, José M. Ferro, MD, PhD https://orcid.org/0000-0002-2343-9097, and Jonathan M. Coutinho, MD, PhD https://orcid.org/0000-0002-8284-982X [email protected] for the Cerebral Venous Sinus Thrombosis With Thrombocytopenia Syndrome Study GroupAuthor Info & Affiliations
Stroke
Volume 53, Number 10
https://doi.org/10.1161/STROKEAHA.122.039575
Track CitationsAdd to favorites
PDF/EPUB

Abstract

Background:

Cerebral venous thrombosis (CVT) due to vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe condition, with high in-hospital mortality rates. Here, we report clinical outcomes of patients with CVT-VITT after SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination who survived initial hospitalization.

Methods:

We used data from an international registry of patients who developed CVT within 28 days of SARS-CoV-2 vaccination, collected until February 10, 2022. VITT diagnosis was classified based on the Pavord criteria. Outcomes were mortality, functional independence (modified Rankin Scale score 0–2), VITT relapse, new thrombosis, and bleeding events (all after discharge from initial hospitalization).

Results:

Of 107 CVT-VITT cases, 43 (40%) died during initial hospitalization. Of the remaining 64 patients, follow-up data were available for 60 (94%) patients (37 definite VITT, 9 probable VITT, and 14 possible VITT). Median age was 40 years and 45/60 (75%) patients were women. Median follow-up time was 150 days (interquartile range, 94–194). Two patients died during follow-up (3% [95% CI, 1%–11%). Functional independence was achieved by 53/60 (88% [95% CI, 78%–94%]) patients. No new venous or arterial thrombotic events were reported. One patient developed a major bleeding during follow-up (fatal intracerebral bleed).

Conclusions:

In contrast to the high mortality of CVT-VITT in the acute phase, mortality among patients who survived the initial hospitalization was low, new thrombotic events did not occur, and bleeding events were rare. Approximately 9 out of 10 CVT-VITT patients who survived the acute phase were functionally independent at follow-up.

Graphical Abstract

Cerebral venous thrombosis (CVT) due to vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare adverse event of adenovirus-based SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccines.1–3 CVT-VITT has substantially higher in-hospital mortality rates (20%–50%), compared with CVT unrelated to VITT (4%).2–4 We aimed to report clinical and functional outcomes of patients with CVT-VITT who survived initial hospitalization.

Methods

We used data from an international registry on CVT after COVID-19 vaccination collected until February 10, 2022. Details have been described.3 Inclusion criteria were radiologically or autopsy-confirmed CVT and symptom onset within 28 days of any SARS-CoV-2 vaccine. The ethical review committee of Amsterdam UMC waived formal approval for this observational study. This article follows the Strengthening the Reporting of Observational Studies in Epidemiology reporting guidelines. Original data are available upon reasonable request.
VITT classification was based on the Pavord criteria2 (Table S1). We included cases with definite, probable, or possible CVT-VITT. We excluded CVT-VITT patients who died during initial hospitalization, patients with missing follow-up data, and cases with CVT after mRNA vaccines, which do not cause VITT.5
We used the information from the last available visit. Outcome measures were mortality, functional independence (modified Rankin Scale score 0–2), VITT relapse after initial clinical remission, new thrombosis, and new major bleeding events according to the criteria of the International Society on Thrombosis and Haemostasis.
Clinical remission was defined as fulfilling the following criteria at any time during follow-up: (1) platelet count >150×109/L; (2) no clinical evidence of new or progressive ischemic organ injury; and (3) no immunomodulatory treatment for 30 days. Relapse was defined as a decrease in platelet count to <150×109/L (with other causes of thrombocytopenia ruled out), with or without clinical evidence of new ischemic organ injury, at any time after achieving clinical remission.
We calculated 95% CI using Wilson score method for main outcomes. Analyses were performed with IBM SPSS Statistics, version 28.0.1.0, RStudio version 1.3.1093 and R version 4.0.3 using the Hmisc package.

Results

Of 208 reported cases, 107 had CVT-VITT. In total, 43 (40%) died during initial hospitalization (Figure S1 and Table S2). Of the remaining 64 patients, follow-up data were available for 60 (94%) patients: 37 (62%) with definite VITT, 9 (15%) probable VITT, and 14 (23%) possible VITT.
Median age was 40 years (interquartile range, 27–56) and 45/60 (75%) patients were women (Table 1). Median follow-up time was 150 days (interquartile range, 94–194, Table 2). Two patients died during follow-up (3% [95% CI, 1%–11%]): one due to a new intracerebral hemorrhage and one of unknown causes (details in Table S3). The latter patient had a new thrombocytopenia during readmission for a COVID-19 infection, fulfilling the criteria for a VITT relapse. No other relapses or bleeding events were reported. No new venous or arterial thrombotic events were reported in any patient. Hospital readmission occurred in 9/54 (17%) cases, 4 of which were for a planned cranioplasty following decompressive hemicraniectomy (Table 2).
Table 1. Patient Details of Initial Hospitalization
 CVT-VITT patients who survived the acute phase (N=60)
Baseline characteristics
 Age, y40 (27–56)
 Female sex45/60 (75)
 Coma4/60 (7)
 Intracerebral hemorrhage30/60 (50)
 Concomitant VTE14/60 (23)
Laboratory data
 Platelet count nadir, x 109/L47 (29–69)
 Positive anti-PF4 antibodies47/53 (89)
 D-dimer level >4 mg/L FEU51/56 (91)
Treatment data
 Anticoagulation60/60 (100)
  Heparin as first anticoagulant*23/60 (38)
 Immunomodulatory treatment44/60 (73)
  Intravenous immunoglobulin44/60 (73)
  Plasma exchange4/60 (7)
  Corticosteroids17/60 (28)
  Other2/60 (3)
 Platelet transfusion10/60 (17)
 Intensive care unit admission37/58 (64)
 Endovascular treatment8/59 (14)
 Decompressive surgery10/59 (17)
Discharge data
 Duration hospital admission, median (IQR; range), d14 (8–26;1–53)†
 Discharge disposition
  Home38/59 (64)
  Rehabilitation center19/59 (32)
  Other hospital2/59 (3)
Discrete data are presented as n/N (%), continuous data as median (IQR). Denominators <60 represent incomplete data points. CVT indicates cerebral venous thrombosis; FEU, fibrinogen equivalent units; IQR, interquartile range; PF4, platelet factor 4; VITT, vaccine-induced immune thrombotic thrombocytopenia; and VTE, venous thrombotic event.
*
Unfractionated heparin or low-molecular weight heparin.
†
Three missing values.
Table 2. Outcomes of Patients Who Survived the Acute Phase of CVT-VITT
 CVT-VITT patients who survived the acute phase (N=60)
Clinical events
 Time from diagnosis to follow-up, d150 (94-194)*
 New VTE0/59
 New ATE0/57
 Major bleeding event1/55 (2)
 Hospital readmission9/54 (17)†
Treatment
 Anticoagulant treatment ongoing at last follow-up44/53 (83)
Outcomes
 Clinical remission achieved41/53 (77)
  Relapse after remission1/35 (3)
 Mortality2/60 (3)
 Returned to work or school21/40 (53)
Discrete data are presented as n/N (%), continuous data as median (IQR). Denominators <60 represent incomplete data points. ATE indicates arterial thrombotic event; CVT, cerebral venous thrombosis; IQR, interquartile range; VITT, vaccine-induced immune thrombotic thrombocytopenia; and VTE, venous thrombotic event.
*
Two missing values. In all cases, date of follow-up was after discharge.
†
Reason readmission (multiple possible): COVID-19 infection (1), cranioplasty (4), encephalopathy (1), headache (1), hepatitis (1), increased intracranial pressure (1), infection (1), inflammatory bowel disease (1), progression of brain metastases (1), and urinary tract infection (1).
Functional independence was achieved by 53/60 (88% [95% CI, 78%–94%]) patients at follow-up, compared with 41/58 (71% [95% CI, 58%–81%]) at hospital discharge (Figure and Figure S2). Overall, 21/40 (53%) patients had returned to work or school at follow-up.
Figure. Modified Rankin Scale (mRS) score of 60 patients with cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia (CVT-VITT) who survived the acute phase, at discharge and at follow-up. Note that CVT-VITT patients who died during initial hospitalization (43/107, 40%) are not included in the Figure. There are 2 missing mRS scores at discharge; both had mRS 0 at follow-up.
Platelet count at follow-up was available for 39/60 (65%) patients, details of which are provided in Figure S3. At least one D-dimer value at follow-up was available for 27/60 (45%) CVT-VITT patients. D-dimer levels declined from >4 mg/L in the acute phase to ≤0.5 mg/L at follow-up in 19/27 (70%) patients (Figure S4).

Discussion

This study indicates that—in sharp contrast to the high mortality rate during the acute phase—mortality of patients with CVT-VITT who survive initial hospitalization is low and new thrombotic and bleeding events rarely occur after discharge. Almost 90% of patients who survived the acute phase were functionally independent at follow-up and half of the patients had returned to work and/or school. One VITT relapse was reported, although not all patients had achieved clinical remission of VITT at follow-up.
The proportion of patients in our study who were functionally independent at follow-up is comparable to the proportion of patients with long-term functional independence after CVT not related to VITT, as reported in the ISCVT (International Study on Cerebral Vein and Dural Sinus Thrombosis; 88% versus 89%, respectively).4 The low number of adverse outcomes in surviving CVT-VITT patients may be explained by the fact that anti-PF4 (platelet factor 4) antibodies, which cause VITT,1 are transient.6 With the disappearance of the anti-PF4 antibodies, the triggering factor for VITT may have resolved.
In a study on the immune type of heparin-induced thrombocytopenia, a disorder that resembles VITT,1 5/28 (18%) patients developed new venous or arterial thrombosis.7 A systematic review on CVT due to heparin-induced thrombocytopenia reported full recovery in only 4/18 (22%) cases, while all other cases had neurological sequelae.8 The higher median age of the patients with CVT due to heparin-induced thrombocytopenia may be one of the explanatory factors for the worse outcome.
This study has limitations. First, because data were collected as part of routine clinical care, duration of follow-up varied and there was no central adjudication of study outcomes. In addition, laboratory tests were often not repeated during follow-up. Second, while follow-up rate was over 90%, we cannot exclude the possibility that clinical events occurred in the 4 patients for which follow-up was missing. Third, the median time from diagnosis to follow-up was ≈5 months. In CVT not related to VITT, recovery can occur up to 1 year after diagnosis, which may indicate that the CVT-VITT patients in this study may still recover further.4
In summary, in contrast to the severity of CVT-VITT during the acute phase, mortality of patients who survived initial hospital admission was low and new thrombotic and bleeding events were rare. Approximately 9 out of 10 CVT-VITT survivors were functionally independent at follow-up.

Article Information

Supplemental Material

Figures S1–S4
Tables S1–S3
References 9,10

Acknowledgments

The conceptualization was done by Drs Jood, Tatlisumak, Heldner, Arnold, Aguiar de Sousa, Ferro, and Coutinho. The methodology was done by Drs van de Munckhof, Lindgren, Ferro, and Coutinho. The validation was done by Dr van de Munckhof. The formal analysis was done by Dr van de Munckhof. The investigation was done by all authors. The resources were done by Drs Ferro and Coutinho. The data curation was done by Drs van de Munckhof, Krzywicka, and Sánchez van Kammen. The writing-original drafted by Drs van de Munckhof, Lindgren, Ferro, and Coutinho. The writing-review and editing were done by all authors. The visualization was done by Drs van de Munckhof, Lindgren, Ferro, and Coutinho. The supervision was done by Drs Ferro and Coutinho. The project administration was done by Drs van de Munckhof, Lindgren, Krzywicka, Poli, Sánchez van Kammen, Scutelnic, Günther, Jood, Tatlisumak, Heldner, Arnold, Aguiar de Sousa, Ferro, and Coutinho. The funding acquisition by Drs Putaala and Coutinho. Drs van de Munckhof and Coutinho had full access to the data in the study and take responsibility for the accuracy of the data analysis.

Footnote

Nonstandard Abbreviations and Acronyms

CVT
cerebral venous thrombosis
ISCVT
International Study on Cerebral Vein and Dural Sinus Thrombosis
PF4
platelet factor 4
VITT
vaccine-induced immune thrombotic thrombocytopenia

Supplemental Material

File (str_stroke-2022-039575d_supp1.pdf)
File (str_stroke-2022-039575d_supp2.pdf)

References

1.
Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384:2092–2101. doi: 10.1056/NEJMoa2104840
Crossref
PubMed
Google Scholar
2.
Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, Rampotas A, Ambler G, Makris M. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021;385:1680–1689. doi: 10.1056/NEJMoa2109908
Crossref
PubMed
Google Scholar
3.
Sánchez van Kammen M, Aguiar de Sousa D, Poli S, Cordonnier C, Heldner MR, van de Munckhof A, Krzywicka K, van Haaps T, Ciccone A, Middeldorp S, et al; Cerebral Venous Sinus Thrombosis With Thrombocytopenia Syndrome Study Group. Characteristics and outcomes of patients with cerebral venous sinus thrombosis in SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. JAMA Neurol. 2021;78:1314–1323. doi: 10.1001/jamaneurol.2021.3619
Crossref
PubMed
Google Scholar
4.
Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35:664–670. doi: 10.1161/01.STR.0000117571.76197.26
Crossref
PubMed
Google Scholar
5.
Krzywicka K, van de Munckhof A, Sánchez van Kammen M, Heldner MR, Jood K, Lindgren E, Tatlisumak T, Putaala J, Kremer Hovinga JA, Middeldorp S, et al. Age-stratified risk of cerebral venous sinus thrombosis after SARS-CoV-2 vaccination. Neurology. 2022;98:e759–e768. doi: 10.1212/WNL.0000000000013148
Crossref
Google Scholar
6.
Schönborn L, Thiele T, Kaderali L, Greinacher A. Decline in pathogenic antibodies over time in VITT. N Engl J Med. 2021;385:1815–1816. doi: 10.1056/NEJMc2112760
Crossref
Google Scholar
7.
Lindhoff-Last E, Wenning B, Stein M, Gerdsen F, Bauersachs R, Wagner R. Risk factors and long-term follow-up of patients with the immune type of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost. 2002;8:347–352. doi: 10.1177/107602960200800406
Crossref
Google Scholar
8.
Aguiar de Sousa D, Romoli M, Sanchez Van Kammen M, Heldner MR, Zini A, Coutinho JM, Arnold M, Ferro JM. Cerebral venous thrombosis in patients with heparin-induced thrombocytopenia a systematic review. Stroke. 2022;53:1892–1903. doi: 10.1161/STROKEAHA.121.036824
Crossref
PubMed
Google Scholar
9.
Ferro JM, Bendszus M, Jansen O, Coutinho JM, Dentali F, Kobayashi A, Aguiar de Sousa D, Neto LL, Miede C, Caria J, et al; RE-SPECT CVT Study Group. Recanalization after cerebral venous thrombosis. A randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous and dural sinus thrombosis. Int J Stroke. 2022;17:189–197. doi: 10.1177/17474930211006303
Crossref
Google Scholar
10.
Günther A, Brämer D, Pletz MW, Kamradt T, Baumgart S, Mayer TE, Baier M, Autsch A, Mawrin C, Schönborn L, et al. Complicated long term vaccine induced thrombotic immune thrombocytopenia-a case report. Vaccines (Basel). 2021;9:1344. doi: 10.3390/vaccines9111344
Crossref
Google Scholar

eLetters(0)

eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.

Sign In to Submit a Response to This Article

Information & Authors

Information

Published In

Go to Stroke
Go to Stroke
Stroke
Volume 53 • Number 10 • October 2022
Pages: 3206 - 3210
PubMed: 36082668

Copyright

© 2022 American Heart Association, Inc.

Versions

You are viewing the most recent version of this article.

History

Received: 1 March 2022
Revision received: 18 July 2022
Accepted: 22 July 2022
Published online: 9 September 2022
Published in print: October 2022

Permissions

Request permissions for this article.

Keywords

  1. hospitalization
  2. intracranial thrombosis
  3. mortality
  4. thrombocytopenia
  5. vaccination
  6. venous thrombosis

Subjects

  1. Cerebrovascular Disease/Stroke
  2. Mortality/Survival
  3. Thrombosis

Authors

Affiliations

Anita van de Munckhof, MD https://orcid.org/0000-0001-6028-3426
Department of Neurology (A.v.d.M., K.K., M.S.v.K., J.M.C.), Amsterdam University Medical Centers, University of Amsterdam, the Netherlands.
View all articles by this author
Erik Lindgren, MD https://orcid.org/0000-0002-7628-5044
Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden (E.L., K.J., T.T.).
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sweden (E.L., K.J., T.T.).
View all articles by this author
Timothy J. Kleinig, MBBS (Hons), PhD https://orcid.org/0000-0003-4430-3276
Department of Neurology, Royal Adelaide Hospital, Adelaide, Australia (T.J.K.).
View all articles by this author
Thalia S. Field, MD, MHSc
Division of Neurology, Vancouver Stroke Program, University of British Columbia, Vancouver, Canada (T.S.F., V.D.).
View all articles by this author
Charlotte Cordonnier, MD, PhD https://orcid.org/0000-0002-5697-6892
University Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, France (C.C., F.C.).
View all articles by this author
Katarzyna Krzywicka, MD, MPhil https://orcid.org/0000-0002-9478-0401
Department of Neurology (A.v.d.M., K.K., M.S.v.K., J.M.C.), Amsterdam University Medical Centers, University of Amsterdam, the Netherlands.
View all articles by this author
Sven Poli, MD, MSc https://orcid.org/0000-0002-0286-8781
Department of Neurology and Stroke, University Hospital Tuebingen (S.P., A.M., J.M.), Eberhard-Karls University, Germany.
Hertie Institute for Clinical Brain Research (S.P., J.M.), Eberhard-Karls University, Germany.
View all articles by this author
Mayte Sánchez van Kammen, MD, MSc https://orcid.org/0000-0001-5614-9689
Department of Neurology (A.v.d.M., K.K., M.S.v.K., J.M.C.), Amsterdam University Medical Centers, University of Amsterdam, the Netherlands.
View all articles by this author
Afshin Borhani-Haghighi, MD
Clinical Neurology Research Center, Shiraz University of Medical Sciences, Iran (A.B.-H.).
View all articles by this author
Robin Lemmens, MD, PhD https://orcid.org/0000-0002-4948-5956
Department of Neurology, University Hospitals Leuven, Belgium (R.L., A.D.).
View all articles by this author
Adrian Scutelnic, MD https://orcid.org/0000-0001-9053-584X
Department of Neurology (A.S., M.R.H., M.A.), Inselspital, Bern University Hospital, University of Bern, Switzerland.
View all articles by this author
Alfonso Ciccone, MD https://orcid.org/0000-0002-4590-3575
Department of Neurology, Carlo Poma Hospital, Azienda Socio Sanitaria Territoriale di Mantova, Mantua, Italy (A. Ciccone).
View all articles by this author
Thomas Gattringer, MD, PhD https://orcid.org/0000-0002-6065-6576
Department of Neurology, Medical University of Graz, Austria (T.G.).
View all articles by this author
Matthias Wittstock, MD, PhD
Department of Neurology, University Hospital Rostock, Germany (M. Wittstock).
View all articles by this author
Vanessa Dizonno, MSc
Division of Neurology, Vancouver Stroke Program, University of British Columbia, Vancouver, Canada (T.S.F., V.D.).
View all articles by this author
Annemie Devroye
Department of Neurology, University Hospitals Leuven, Belgium (R.L., A.D.).
View all articles by this author
Ahmed Elkady, MD, MSc
Department of Neurology, Saudi German Hospital, Jeddah, Saudi Arabia (A.E.).
View all articles by this author
Albrecht Günther, MD https://orcid.org/0000-0002-2394-3947
Department of Neurology, Jena University Hospital, Germany (A.G.).
View all articles by this author
Alvaro Cervera, MD, PhD https://orcid.org/0000-0002-6644-0020
Royal Darwin Hospital, Darwin, Northern Territory, Australia (A. Cervera).
View all articles by this author
Annerose Mengel, MD https://orcid.org/0000-0002-2399-3020
Department of Neurology and Stroke, University Hospital Tuebingen (S.P., A.M., J.M.), Eberhard-Karls University, Germany.
View all articles by this author
Beng Lim Alvin Chew, MD
Department of Neurology, John Hunter Hospital, Newcastle, Australia (B.L.A.C., C.G.-E.).
View all articles by this author
Brian Buck, MD https://orcid.org/0000-0002-7984-6062
Division of Neurology, University of Alberta Hospital, Edmonton, Canada (B.B.).
View all articles by this author
Carla Zanferrari, MD
Department of Neurology, Azienda Ospedaliera di Melegnano e della Martesana, Italy (C.Z.).
View all articles by this author
Carlos Garcia-Esperon, MD, PhD
Department of Neurology, John Hunter Hospital, Newcastle, Australia (B.L.A.C., C.G.-E.).
View all articles by this author
Christian Jacobi, MD https://orcid.org/0000-0002-9611-3805
Department of Neurology, Krankenhaus Nordwest, Frankfurt am Main, Germany (C.J.).
View all articles by this author
Cristina Soriano, MD
Department of Neurology, Hospital General de Castellón, Castelló, Spain (C.S.).
View all articles by this author
Dominik Michalski, MD https://orcid.org/0000-0002-0206-5380
Department of Neurology, Leipzig University Hospital, Germany (D.M., J. Pelz).
View all articles by this author
Zohreh Zamani, MD
Department of Neurology, Firoozabadi Hospital (Z.Z.), Firoozgar Hospital, School of Medicine, Iran University of Medical Sciences, Tehran.
View all articles by this author
Dylan Blacquiere, MD
Division of Neurology, The Ottawa Hospital, Canada (D.B.).
View all articles by this author
Elias Johansson, MD, PhD https://orcid.org/0000-0001-5317-4563
Department Clinical Science, Wallenberg Center for Molecular Medicine (WCMM), Umeå University, Sweden (E.J.).
View all articles by this author
Elisa Cuadrado-Godia, MD, PhD https://orcid.org/0000-0002-9147-875X
Department of Neurology, University Hospital del Mar, Barcelona, Spain (E.C.-G.).
View all articles by this author
Fabrice Vuillier, MD, PhD
Stroke Unit, University Hospital of Besancon, France (F.V.).
View all articles by this author
Felix J. Bode, MD https://orcid.org/0000-0003-4498-186X
Department of Neurology, Universitätsklinikum Bonn, Germany (F.J.B., J.Z.).
View all articles by this author
François Caparros, MD https://orcid.org/0000-0002-6627-0893
University Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, France (C.C., F.C.).
View all articles by this author
Frank Maier, MD
Department of Neurology, Caritas Hospital Saarbrücken, Germany (F.M.).
View all articles by this author
Georgios Tsivgoulis, MD, PhD https://orcid.org/0000-0002-0640-3797
Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, Greece (G.T.).
View all articles by this author
Hans D. Katzberg, MD
Department of Neuromuscular Medicine, Toronto General Hospital, Canada (H.D.K.).
View all articles by this author
Jiangang Duan, MD, PhD https://orcid.org/0000-0002-8849-2120
Department of Neurology and Emergency, Xuanwu Hospital, Capital Medical University, Beijing, China (J.D.).
View all articles by this author
Jim Burrow, MD
Department of Neurology, Royal Darwin Hospital, Tiwi, Australia (J.B.).
View all articles by this author
Johann Pelz, MD
Department of Neurology, Leipzig University Hospital, Germany (D.M., J. Pelz).
View all articles by this author
Joshua Mbroh, MD, MSc https://orcid.org/0000-0002-0108-9161
Department of Neurology and Stroke, University Hospital Tuebingen (S.P., A.M., J.M.), Eberhard-Karls University, Germany.
Hertie Institute for Clinical Brain Research (S.P., J.M.), Eberhard-Karls University, Germany.
View all articles by this author
Joyce Oen, MD
Department of Neurology, Antonius Ziekenhuis, Sneek, the Netherlands (J.O.).
View all articles by this author
Judith Schouten, MD, PhD
Department of Neurology, Rijnstate Hospital Arnhem, the Netherlands (J.S.).
View all articles by this author
Julian Zimmermann, MD https://orcid.org/0000-0003-1964-0078
Department of Neurology, Universitätsklinikum Bonn, Germany (F.J.B., J.Z.).
View all articles by this author
Karl Ng, MBBS (Hons 1), PhD https://orcid.org/0000-0001-7973-3773
Department of Neurology, Royal North Shore Hospital, Sydney, Australia (K.N., M. Wronski, S.C.).
View all articles by this author
Katia Garambois, MD, PhD
Department of Neurology, CHU Grenoble Alpes, France (K.G., P.C.).
View all articles by this author
Marco Petruzzellis, MD https://orcid.org/0000-0001-7413-6355
Department of Neurology, AOU Consorziale Policlinico di Bari, Italy (M.P.).
View all articles by this author
Mariana Carvalho Dias, MD https://orcid.org/0000-0002-6603-1796
Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte, University of Lisbon, Portugal (M.C.D.).
View all articles by this author
Masoud Ghiasian, MD
Department of Neurology, Sina Hospital, Hamadan University of Medical Science, Iran (M.G.).
View all articles by this author
Michele Romoli, MD https://orcid.org/0000-0001-8009-8543
Neurology and Stroke Unit, Department of Neuroscience, Bufalini Hospital, Cesena, Italy (M.R.).
View all articles by this author
Miguel Miranda, MD, MSc https://orcid.org/0000-0001-5285-1665
Department of Neurology, Hospital de Cascais Dr. José de Almeida, Cascais, Portugal (M.M.).
View all articles by this author
Miriam Wronski, MD https://orcid.org/0000-0003-4888-7707
Department of Neurology, Royal North Shore Hospital, Sydney, Australia (K.N., M. Wronski, S.C.).
View all articles by this author
Mona Skjelland, MD, PhD
Department of Neurology, Oslo University Hospital, Norway (M.S.).
View all articles by this author
Mostafa Almasi-Dooghaee, MD https://orcid.org/0000-0002-3244-1615
Department of Neurology (M.A.-D., Z.M.), Firoozgar Hospital, School of Medicine, Iran University of Medical Sciences, Tehran.
View all articles by this author
Pauline Cuisenier, MD
Department of Neurology, CHU Grenoble Alpes, France (K.G., P.C.).
View all articles by this author
Seán Murphy, MD
Acute Stroke Service, Mater Misericordiae University Hospital, UCD School of Medicine and RCSI Medical School, Dublin, Ireland (S. Murphy).
View all articles by this author
Serge Timsit, MD, PhD https://orcid.org/0000-0003-0346-8576
Department of Neurology, Stroke Unit, Hôpital de la Cavale Blanche, CHRU de Brest (University Hospital), Université de Bretagne Occidentale, Inserm 1078, Brest, France (S.T.).
View all articles by this author
Shelagh B. Coutts, MD, MSc https://orcid.org/0000-0001-5090-5105
Department of Clinical Neurosciences, Radiology, and Community Health Sciences, Foothills Medical Centre, Calgary, Canada (S.B.C.).
View all articles by this author
Silvia Schönenberger, MD
Department of Neurology, Heidelberg University Hospital, Germany (S.S., S.N.).
View all articles by this author
Simon Nagel, MD https://orcid.org/0000-0003-2471-6647
Department of Neurology, Heidelberg University Hospital, Germany (S.S., S.N.).
View all articles by this author
Sini Hiltunen, MD, PhD
Department of Neurology, Helsinki University Hospital, University of Helsinki, Finland (S.H., T.T., J. Putaala).
View all articles by this author
Sophie Chatterton, MD https://orcid.org/0000-0003-4296-9285
Department of Neurology, Royal North Shore Hospital, Sydney, Australia (K.N., M. Wronski, S.C.).
View all articles by this author
Thomas Cox, MD
Department of Neurology, University Hospital Southampton NHS Foundation Trust, United Kingdom (T.C.).
View all articles by this author
Thorsten Bartsch, MD, PhD https://orcid.org/0000-0001-8387-5731
Department of Neurology, University Medical Center Schleswig-Holstein, Campus Kiel, Germany (T.B.).
View all articles by this author
Vahid Shaygannejad, MD
Isfahan University of Medical Sciences (IUMS), Isfahan Neurosciences Research Center (INRC), Iran (V.S.).
Department of Internal (INRC), Iran (V.S.).
View all articles by this author
Zahra Mirzaasgari, MD
Department of Neurology (M.A.-D., Z.M.), Firoozgar Hospital, School of Medicine, Iran University of Medical Sciences, Tehran.
View all articles by this author
Saskia Middeldorp, MD, PhD https://orcid.org/0000-0002-1006-6420
Department of Internal Medicine and Radboud Institute of Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands (S. Middeldorp).
View all articles by this author
Marcel M. Levi, MD, PhD
Department of Vascular Medicine (M.M.L.), Amsterdam University Medical Centers, University of Amsterdam, the Netherlands.
National Institute for Health Research, University College London Hospitals (UCLH), Biomedical Research Centre, London, United Kingdom (M.M.L.).
View all articles by this author
Johanna A. Kremer Hovinga, MD https://orcid.org/0000-0002-1300-7135
Department of Hematology (J.A.K.H.), Inselspital, Bern University Hospital, University of Bern, Switzerland.
View all articles by this author
Katarina Jood, MD, PhD
Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden (E.L., K.J., T.T.).
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sweden (E.L., K.J., T.T.).
View all articles by this author
Turgut Tatlisumak, MD, PhD https://orcid.org/0000-0002-2430-8988
Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden (E.L., K.J., T.T.).
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sweden (E.L., K.J., T.T.).
Department of Neurology, Helsinki University Hospital, University of Helsinki, Finland (S.H., T.T., J. Putaala).
View all articles by this author
Jukka Putaala, MD, PhD https://orcid.org/0000-0002-6630-6104
Department of Neurology, AOU Consorziale Policlinico di Bari, Italy (M.P.).
View all articles by this author
Mirjam R. Heldner, MD, MSc https://orcid.org/0000-0002-3594-2159
Department of Neurology (A.S., M.R.H., M.A.), Inselspital, Bern University Hospital, University of Bern, Switzerland.
View all articles by this author
Marcel Arnold, MD
Department of Neurology (A.S., M.R.H., M.A.), Inselspital, Bern University Hospital, University of Bern, Switzerland.
View all articles by this author
Diana Aguiar de Sousa, MD, PhD
Stroke Centre, Lisbon Central University Hospital Centre, Portugal (D.A.d.S.).
Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Portugal (D.A.d.S., J.M.F.).
View all articles by this author
José M. Ferro, MD, PhD* https://orcid.org/0000-0002-2343-9097
Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Portugal (D.A.d.S., J.M.F.).
View all articles by this author
Jonathan M. Coutinho, MD, PhD* https://orcid.org/0000-0002-8284-982X [email protected]
Department of Neurology (A.v.d.M., K.K., M.S.v.K., J.M.C.), Amsterdam University Medical Centers, University of Amsterdam, the Netherlands.
View all articles by this author
for the Cerebral Venous Sinus Thrombosis With Thrombocytopenia Syndrome Study Group
View all articles by this author

Notes

*
J.M. Ferro and J.M. Coutinho are joint last authors.
This manuscript was sent to Scott E. Kasner, Guest Editor, for review by expert referees, editorial decision, and final disposition.
Supplemental Material is available at Supplemental Material.
For Sources of Funding and Disclosures, see page 3210.
Correspondence to: Jonathan M. Coutinho, MD, PhD, Department of Neurology, Amsterdam UMC, location AMC, Meibergdreef 9, Amsterdam, the Netherlands. Email [email protected]

Disclosures

Disclosures Dr Lindgren has received academic grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement (ALFGBG 942851), Swedish Neurological Society, Elsa and Gustav Lindh’s Foundation, Wennerströms’ Foundation, P-O Ahl’s Foundation and Rune and Ulla Amlöv’s Foundation for research on cerebral venous thrombosis (CVT). Dr Kleinig has received educational meeting cost assistance from Boehringer Ingelheim. Dr Field receives in-kind study medication from Bayer Canada, advisory board honoraria from HLS Therapeutics, compensation from BMS-Pfizer for consultant services, grants from Heart and Stroke Foundation of Canada, stock holdings in Destine Health, and service as Board Member for Destine Health. Dr Cordonnier has received speaker honoraria from Boehringer Ingelheim, personal fees for advisory board participation from AstraZeneca and Biogen, and personal fees for steering committee participation from Biogen and Bristol Myers Squibb. Dr Poli received research support from BMS/Pfizer, Boehringer Ingelheim, Daiichi Sankyo, European Union, German Federal Joint Committee Innovation Fund, and German Federal Ministry of Education and Research, Helena Laboratories and Werfen as well as speakers’ honoraria/consulting fees from Alexion, AstraZeneca, Bayer, Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo, Portola, and Werfen (all outside the submitted work). Dr Lemmens reports fees paid to his institution for consultancy by Boehringer Ingelheim, Genentech, Ischemaview, Medtronic, and Medpass. Dr Scutelnic has received a grant from Swiss Heart Foundation. Dr Ciccone received speaker grants from Alexion Pharma, Italfarmaco, and Daiichi Sankyo. Dr Gattringer has received travel grants and speaker honoraria from Boehringer Ingelheim, Bayer, Novartis, BMS/Pfizer, and Alexion. Dr Wittstock has received consulting fees from Portola/Alexion. Dr Günther has received personal fees from Bayer Vital, Bristol Myers Squibb, and Daiichi Sankyo, and compensation from Boehringer Ingelheim, Ipsen Pharma SAS, and PFIZER PHARMA GMBH for other services. Dr Jacobi has received speaker honoraria from Alexion, CSL Behring, TEVA, and Sanofi-Aventis and personal fees for advisory board participation from Alexion, Roche, Sanofi-Aventis, and Merck Serono. Dr Johansson reports grants from Hjärt-Lungfonden, STROKE-Riksförbundet, Knut och Alice Wallenbergs Stiftelse, Jeanssons Stiftelser, the Research fund for Neurological Research at the University Hospital of Northern Sweden, The Northern Swedish fund for stroke research, Region Västerbotten, and the research fund at Umeå University. Dr Katzberg has received personal fees for consulting and data safety monitoring board activities for Octapharma, Grifols, CSL Behring, UCB, Argenx, Takaeda, and Alexion, compensation from Alnylam Pharmaceuticals and Merz Pharma (Schweiz) AG for consultant services, and his institution has received clinical trial support from Takaeda. Dr Nagel has received consulting fees from Brainomix and lecture fees from Boehringer Ingelheim and BMS-Pfizer. Dr Middeldorp reports grants from Bayer, Pfizer, Boehringer Ingelheim, and Daiichi Sankyo paid to her institution, personal fees from Bayer, BMS/Pfizer, Boehringer Ingelheim, Abbvie, Portola/Alexion, and Daiichi Sankyo paid to her institution, and compensation from Sanofi and Viatris for other services. Dr Jood has received academic grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement (ALFGBG 965417) for research on CVT. Dr Tatlisumak has received personal fees from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Inventiva, and Portola Pharma. Dr Heldner reports grants from the Swiss Heart Foundation, the Bangerter Foundation, Swiss National Science Foundation, and SITEM Research Funds, and Advisory Board participation for Amgen. Dr Arnold reports compensation from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Covidien, Daiichi Sankyo, Novartis, Sanofi, Pfizer, Medtronic and research grants from the Swiss National Science Foundation and the Swiss Heart Foundation. Dr Aguiar de Sousa reports travel support from Boehringer Ingelheim, speaker fees from Bayer, Advisory Board participation for AstraZeneca, compensation from University of British Columbia for data and safety monitoring services, and compensation from Faculdade de Medicina da Universidade de Lisboa for other services. Dr Ferro has received personal fees from Boehringer Ingelheim, Bayer, and Daiichi Sankyo as well as grants from Bayer. Dr Coutinho has received grants paid to his institution from Boehringer Ingelheim, Medtronic, and Bayer, compensation from PORTOLA PHARMACEUTICALS LLC for consultant services, and payments paid to his institution for data safety monitoring board participation by Bayer. The other authors report no conflicts.

Sources of Funding

This study was funded by the Netherlands Organisation for Health Research and Development (ZonMw, grant number 10430072110005), the Dr. C.J. Vaillant Foundation, and Hospital District of Helsinki and Uusimaa (grant TYH2022223).

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

    • Leonidas Panos,
    • Panagiotis Bargiotas,
    • Georgios Hadjigeorgiou,
    • Georgios Panos,
    Neurovascular Adverse Effects of Sars-Cov-2 Vaccination, Drug Design, Development and Therapy, Volume 18, (1891-1905), (2024).https://doi.org/10.2147/DDDT.S464394
    Crossref
    • Gustavo Saposnik,
    • Cheryl Bushnell,
    • Jonathan M. Coutinho,
    • Thalia S. Field,
    • Karen L. Furie,
    • Najibah Galadanci,
    • Wayneho Kam,
    • Fenella C. Kirkham,
    • Norma D. McNair,
    • Aneesh B. Singhal,
    • Vincent Thijs,
    • Victor X.D. Yang,
    Diagnosis and Management of Cerebral Venous Thrombosis: A Scientific Statement From the American Heart Association, Stroke, 55, 3, (e77-e90), (2024)./doi/10.1161/STR.0000000000000456
    Abstract
    • Talal Al-Mayhani,
    • Richard Perry,
    Cerebral Venous Thrombosis Due to Vaccine-Induced Thrombotic Thrombocytopenia, Stroke Medicine, (165-171), (2024).https://doi.org/10.1007/978-3-031-58188-5_21
    Crossref
    • Josef Finsterer,
    Neurological Adverse Reactions to SARS-CoV-2 Vaccines, Clinical Psychopharmacology and Neuroscience, 21, 2, (222-239), (2023).https://doi.org/10.9758/cpn.2023.21.2.222
    Crossref
    • Renat Roytenberg,
    • Adolfo García-Sastre,
    • Wei Li,
    Vaccine-induced immune thrombotic thrombocytopenia: what do we know hitherto?, Frontiers in Medicine, 10, (2023).https://doi.org/10.3389/fmed.2023.1155727
    Crossref
    • Johannes Weller,
    • Katarzyna Krzywicka,
    • Anita van de Munckhof,
    • Franziska Dorn,
    • Katharina Althaus,
    • Felix J Bode,
    • Monica Bandettini di Poggio,
    • Brian Buck,
    • Timothy Kleinig,
    • Charlotte Cordonnier,
    • Vanessa Dizonno,
    • Jiangang Duan,
    • Ahmed Elkady,
    • Beng Lim Alvin Chew,
    • Carlos Garcia-Esperon,
    • Thalia S Field,
    • Catherine Legault,
    • Mar Morin Martin,
    • Dominik Michalski,
    • Johann Pelz,
    • Silvia Schoenenberger,
    • Simon Nagel,
    • Marco Petruzzellis,
    • Nicolas Raposo,
    • Mona Skjelland,
    • Domenico Sergio Zimatore,
    • Sanjith Aaron,
    • Mayte Sanchez van Kammen,
    • Diana Aguiar de Sousa,
    • Erik Lindgren,
    • Katarina Jood,
    • Adrian Scutelnic,
    • Mirjam R Heldner,
    • Sven Poli,
    • Antonio Arauz,
    • Adriana B Conforto,
    • Jukka Putaala,
    • Turgut Tatlisumak,
    • Marcel Arnold,
    • Jonathan M Coutinho,
    • Albrecht Günther,
    • Julian Zimmermann,
    • José M Ferro,
    Endovascular treatment of cerebral sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia, European Stroke Journal, 9, 1, (105-113), (2023).https://doi.org/10.1177/23969873231202363
    Crossref
    • Katarzyna Krzywicka,
    • Diana Aguiar de Sousa,
    • Charlotte Cordonnier,
    • Felix J. Bode,
    • Thalia S. Field,
    • Dominik Michalski,
    • Johann Pelz,
    • Mona Skjelland,
    • Markus Wiedmann,
    • Julian Zimmermann,
    • Matthias Wittstock,
    • Bruno Zanotti,
    • Alfonso Ciccone,
    • Monica Bandettini di Poggio,
    • Afshin Borhani‐Haghighi,
    • Sophie Chatterton,
    • Avinash Aujayeb,
    • Annemie Devroye,
    • Vanessa Dizonno,
    • Thomas Geeraerts,
    • Fabrizio Giammello,
    • Albrecht Günther,
    • Nasli R. Ichaporia,
    • Timothy Kleinig,
    • Espen S. Kristoffersen,
    • Robin Lemmens,
    • Emmanuel De Maistre,
    • Zahra Mirzaasgari,
    • Jean‐Francois Payen,
    • Jukka Putaala,
    • Marco Petruzzellis,
    • Nicolas Raposo,
    • Elyar Sadeghi‐Hokmabadi,
    • Silvia Schoenenberger,
    • Meenakshisundaram Umaiorubahan,
    • Padmavathy N Sylaja,
    • Anita van de Munckhof,
    • Mayte Sánchez van Kammen,
    • Erik Lindgren,
    • Katarina Jood,
    • Adrian Scutelnic,
    • Mirjam R. Heldner,
    • Sven Poli,
    • Marieke J. H. A. Kruip,
    • Antonio Arauz,
    • Adriana B. Conforto,
    • Sanjith Aaron,
    • Saskia Middeldorp,
    • Turgut Tatlisumak,
    • Marcel Arnold,
    • Jonathan M. Coutinho,
    • José M. Ferro,
    Decompressive surgery in cerebral venous sinus thrombosis due to vaccine‐induced immune thrombotic thrombocytopenia, European Journal of Neurology, 30, 5, (1335-1345), (2023).https://doi.org/10.1111/ene.15735
    Crossref
    • Bianca Clerici,
    • Eleonora Pontisso,
    • Chiara Aloise,
    • Benedetta Peroni,
    • Rosaria Perricone,
    • Chiara Pisetta,
    • Mariangela Scavone,
    • Simone Birocchi,
    • Gian Marco Podda,
    Thrombosis and Bleeding in Patients with Vaccine-Induced Immune Thrombotic Thrombocytopenia: A Systematic Review of Published Cases, Thrombosis and Haemostasis, 124, 05, (423-431), (2023).https://doi.org/10.1055/s-0043-1777134
    Crossref
    • Marc Dinkin,
    • Swetha Sathi,
    Neuro-Ophthalmic Visual Impairment in the Setting of COVID-19, Seminars in Neurology, 43, 02, (268-285), (2023).https://doi.org/10.1055/s-0043-1767715
    Crossref
    • Eleonora Petito,
    • Paolo Gresele,
    Vaccine-Induced Immune Thrombotic Thrombocytopenia Two Years Later: Should It Still Be on the Scientific Agenda?, Thrombosis and Haemostasis, (2023).https://doi.org/10.1055/a-2107-0891
    Crossref
  11. See more

View Options

View options

PDF and All Supplements

Download PDF and All Supplements

PDF/EPUB

View PDF/EPUB
Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Save for later Item saved, go to cart
Purchase Options

Purchase this article to access the full text.

Purchase access to this journal for 24 hours

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

Media

Figures

Other

Tables

Share

Share

Share article link

Share

View full text|Download PDF

Comment Response